TRAIL apoptotic pathway-targeted therapies for NSCLC
Authors:
Open Access
- 1 June 2012
- journal article
- editorial
- Vol. 1 (2) , 155-157-157
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutationsJournal of Clinical Oncology, 2008
- Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced CancersClinical Cancer Research, 2007
- Lipid Rafts and Nonrafts Mediate Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptotic and Nonapoptotic Signals in Non–Small Cell Lung Carcinoma CellsCancer Research, 2007
- Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1Journal of Clinical Oncology, 2007
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Gefitinib — a novel targeted approach to treating cancerNature Reviews Cancer, 2004
- Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versionsNature Medicine, 2001
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994